Jump Financial’s Karyopharm Therapeutics KPTI Stock Holding History

Jump Financial’s Portfolio KPTI Stock Details KPTI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.46M	Buy	262,146 +208,330	+387%	+$1.59M	0.02%	781
2025 Q4	$396K	Buy	+53,816	New	+$329K	﹤0.01%	1420
2024 Q3	–	Sell	-1,787	Closed	-$23.3K	–	1896
2024 Q2	$23.3K	Buy	+1,787	New	+$29.6K	﹤0.01%	1703
2023 Q1	–	Sell	-3,898	Closed	-$199K	–	1822
2022 Q4	$199K	Buy	+3,898	New	+$270K	0.01%	1294
2022 Q3	–	Sell	-809	Closed	-$54K	–	1773
2022 Q2	$54K	Buy	+809	New	+$74.2K	﹤0.01%	1496
2022 Q1	–	Sell	-5,708	Closed	-$551K	–	1727
2021 Q4	$551K	Buy	+5,708	New	+$569K	0.03%	608
2021 Q3	–	Sell	-4,686	Closed	-$725K	–	1302
2021 Q2	$725K	Buy	4,686 +519	+12%	+$75.3K	0.07%	354
2021 Q1	$658K	Buy	+4,167	New	+$878K	0.06%	334

Other funds holding KPTI

Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

CCM

Catalio Capital Management New York $479M AUM 140.7% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

AAA

Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return

Jump Financial's KPTI Position: Q1 2026 in Review

Jump Financial increased its Karyopharm Therapeutics (KPTI) stake by 387% in Q1 2026, buying an estimated $1.59M and bringing the position to 262,146 shares worth $1.46M. The position accounts for 0.02% of the portfolio, ranked #781.

Jump Financial first reported a position in KPTI in Q1 2021 and has held it in 8 quarters since. 77 funds tracked by Wall St. Rank hold KPTI as of Q1 2026.

Jump Financial held 262,146 shares of Karyopharm Therapeutics worth $1.46M as of Q1 2026.
Jump Financial bought 208,330 Karyopharm Therapeutics shares in Q1 2026, an estimated $1.59M.
Karyopharm Therapeutics made up 0.02% of Jump Financial's portfolio in Q1 2026, its #781 holding.
Jump Financial first reported a position in Karyopharm Therapeutics in Q1 2021 and has held it in 8 quarters since.
77 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q1 2026.

Based on Jump Financial's 13F filing for Q1 2026, filed 14 May 2026.